New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:14 EDTACURAcura Pharma downgraded to Hold from Buy at MLV & Co.
MLV & Co. Acura following the announcement that the FDA advised the company that the data from the company's intranasal abuse liability study AP-ADF-301 for the company's AVERSION hydrocodone bitartrate with acetaminophen product candidate are insufficient to support an intranasal abuse deterrence claim.
News For ACUR From The Last 14 Days
Check below for free stories on ACUR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
06:18 EDTACURAcura Pharma awarded NIH grant to fund drug abuse deterrent technology
Acura Pharmaceuticals has been awarded a $300K grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology. The Grant is based on a proposal submitted by the company to advance the development of a self-regulating hydromorphone tablet intended to deter abuse by excess oral consumption of the tablets. The company must complete Phase I development by February 28, 2015. Phase I of the project is intended to optimize the formulation in preparation for clinical testing in Phase II. NIDA funding of Phase II development, for which an application has already been submitted, will be contingent upon Phase I progress, approval of other documents and availability of funds.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use